Old Web
PCN96 US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI